AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 471152 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-196 (20, 40, 60, 80 mg)
Number of subjects: 5
Study 471152 — intervention group
Group type: COMPARATOR
Intervention: Frusemide (40 mg)
Number of subjects: 5
Study 12756629 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented fusion
Number of subjects: 109
Study 12756629 — intervention group
Group type: COMPARATOR
Intervention: Non-instrumented fusion
Number of subjects: 109
Study 12756629 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-organic pain group
Number of subjects: 109
Study 12756629 — intervention group
Group type: EXPERIMENTAL
Intervention: Working patients
Number of subjects: 109
Study 12756629 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall spinal fusion patients
Number of subjects: 109
Study 12756629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain drawings
Number of subjects: 109
Study 29597305 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol with carbohydrate (25 g sucrose)
Number of subjects: 32
Study 29597305 — intervention group
Group type: COMPARATOR
Intervention: Alcohol with artificial sweetener (aspartame)
Number of subjects: 32
Study 29597305 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (20 g for males; 10 g for females)
Number of subjects: 32
Study 29597305 — intervention group
Group type: EXPERIMENTAL
Intervention: NDARC advised alcohol quantities
Number of subjects: 32
Study 29597305 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol with artificially-sweetened mixers
Number of subjects: 32
Study 26581681 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 g walnuts/d
Number of subjects: 18
Study 26581681 — intervention group
Group type: COMPARATOR
Intervention: unsupplemented base diet
Number of subjects: 18
Study 25060482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (highest levels)
Number of subjects: 1730
Study 25060482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (second quartile)
Number of subjects: 1730
Study 25060482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (third quartile)
Number of subjects: 1730
Study 25060482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (fourth quartile)
Number of subjects: 1730
Study 22496174 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐ to 10‐minute educational intervention in a pediatric clinic
Number of subjects: 129
Study 20647083 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative apical pressure device (EndoVac; Discus Dental, Culver City, CA)
Number of subjects: 110
Study 20647083 — intervention group
Group type: COMPARATOR
Intervention: Needle irrigation (Max‐i‐Probe; Dentsply Rinn, Elgin, IL)
Number of subjects: 110
Study 18823180 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 0
Study 16644335 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized biventricular pacing (OPT)
Number of subjects: 121
Study 16644335 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous biventricular pacing
Number of subjects: 121
Study 16644335 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D (both groups)
Number of subjects: 121
Study 12544674 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant‐estrogen, intermittent‐progestogen hormone replacement regimen (Ortho‐Prefest)
Number of subjects: 119
Study 12544674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 11018622 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanotan II (0.025 mg/kg)
Number of subjects: 10
Study 11018622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9054308 — intervention group
Group type: EXPERIMENTAL
Intervention: Forlax
Number of subjects: 256
Study 9054308 — intervention group
Group type: COMPARATOR
Intervention: Transipeg
Number of subjects: 256
Study 1633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric stoop lifting efforts with 60 degrees hip flexion
Number of subjects: 30
Study 1633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric stoop lifting efforts with 90 degrees hip flexion
Number of subjects: 30
Study 1633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squat lifting efforts with 90 degrees knee flexion
Number of subjects: 30
Study 1633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric squat lifting efforts with 135 degrees knee flexion
Number of subjects: 30
Study 1633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic lifts at 50cm/s
Number of subjects: 30
Study 1633793 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected optimal postures
Number of subjects: 30
Study 6437579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg once daily
Number of subjects: 197
Study 6437579 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 197
Study 31091064 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMER protocol (intrauterine PRP injection and subcutaneous G-CSF injection)
Number of subjects: 33
Study 31091064 — intervention group
Group type: COMPARATOR
Intervention: Control group (first IVF/ICSI attempt without PRP or G-CSF injection)
Number of subjects: 33
Study 30030584 — intervention group
Group type: EXPERIMENTAL
Intervention: GLIF combination chemotherapy (gemcitabine 800 mg/m2, levofolinate 100 mg/m2, irinotecan 80 mg/m2, 5-FU 1000 mg/m2)
Number of subjects: 28
Study 25933139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin treatment
Number of subjects: 52
Study 25933139 — intervention group
Group type: EXPERIMENTAL
Intervention: Very rapid virologic response (VRVR) group (1.5 log decrease in HCV RNA levels at the first week)
Number of subjects: 52
Study 25933139 — intervention group
Group type: COMPARATOR
Intervention: Non-VRVR group (without 1.5 log decrease in HCV RNA levels at the first week)
Number of subjects: 52
Study 25933139 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid virologic response group
Number of subjects: 52
Study 25933139 — intervention group
Group type: EXPERIMENTAL
Intervention: Early virologic response group
Number of subjects: 52
Study 24041564 — intervention group
Group type: EXPERIMENTAL
Intervention: VoorZorg programme (nurse home visitation intervention)
Number of subjects: 460
Study 24041564 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 460
Study 22551472 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Programme 10-14 (SFP10-14)
Number of subjects: 0
Study 22551472 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 0
Study 20403817 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic atrial fibrillation (AF) in patients with ischaemic heart disease (IHD)
Number of subjects: 2881
Study 20403817 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic atrial fibrillation (AF) in patients without ischaemic heart disease (IHD)
Number of subjects: 2881
Study 17908884 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 80
Study 17908884 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 80
Study 16055231 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined two-dose hepatitis A and B vaccine (720ELU HAV, 20 mcg HBsAg)
Number of subjects: 511
Study 16055231 — intervention group
Group type: COMPARATOR
Intervention: Established three-dose hepatitis A and B vaccine (360ELU HAV, 10 mcg HBsAg)
Number of subjects: 511
Study 12015785 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective pretest ratings
Number of subjects: 251
Study 12015785 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective assessments
Number of subjects: 251
Study 12015785 — intervention group
Group type: COMPARATOR
Intervention: Current assessments
Number of subjects: 251
Study 10028739 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving (Regent 'Reveal' perforation indication system or standard surgical gloves)
Number of subjects: 138
Study 10028739 — intervention group
Group type: COMPARATOR
Intervention: Single gloves (Regent Biogel D or standard surgical gloves)
Number of subjects: 138
Study 10028739 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove perforation indication system
Number of subjects: 138
Study 7782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (monamine oxidase inhibitor)
Number of subjects: 0
Study 7782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (reversible monamine oxidase inhibitor)
Number of subjects: 0
Study 7782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (reversible monamine oxidase inhibitor)
Number of subjects: 0
Study 7782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (serotonin selective reuptake inhibitor)
Number of subjects: 0
Study 7782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (serotonin selective reuptake inhibitor)
Number of subjects: 0
Study 7782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (benzodiazepine)
Number of subjects: 0
Study 7782272 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐adrenergic receptor blockers
Number of subjects: 0
Study 2274738 — intervention group
Group type: EXPERIMENTAL
Intervention: K type pouch
Number of subjects: 30
Study 2274738 — intervention group
Group type: COMPARATOR
Intervention: J type pouch
Number of subjects: 30
Study 2274738 — intervention group
Group type: EXPERIMENTAL
Intervention: STP patients
Number of subjects: 30
Study 2274738 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (endoanal mucosectomy and hand-sutured pouch-anal anastomosis)
Number of subjects: 30
Study 6270994 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diet
Number of subjects: 309
Study 6270994 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil
Number of subjects: 309
Study 6270994 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk of magnesia and cascara
Number of subjects: 309
Study 6270994 — intervention group
Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 309
Study 31881181 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVIA Centaur® XP system for insulin determination
Number of subjects: 48
Study 31881181 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin assay applied in bioequivalence study of miglitol
Number of subjects: 48
Study 31848175 — intervention group
Group type: EXPERIMENTAL
Intervention: CPES responders
Number of subjects: 103186
Study 31848175 — intervention group
Group type: COMPARATOR
Intervention: Cancer registry population
Number of subjects: 103186
Study 28276638 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg/year
Number of subjects: 285
Study 28276638 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg treatment
Number of subjects: 285
Study 28276638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 28276638 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg
Number of subjects: 285
Study 27669539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea without vomiting
Number of subjects: 797
Study 27669539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea with vomiting
Number of subjects: 797
Study 27669539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea
Number of subjects: 797
Study 23895390 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of interpupillary distance (IPD) as the unit for binocular perception of distance using vergence angles.
Number of subjects: 0
Study 23895390 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of eye height (EH) as the unit for monocular perception of distance using elevation angles.
Number of subjects: 0
Study 23895390 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation of simultaneously available IPD and EH units.
Number of subjects: 0
Study 22305183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetylcysteine (50 mg/kg/hr for 2 hrs before contrast exposure, then 20 mg/kg/hr for 5 hrs)
Number of subjects: 0
Study 22305183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetylcysteine (1200 mg twice daily for 2 days, starting the day before contrast exposure)
Number of subjects: 0
Study 22305183 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19914558 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions from randomized controlled trials
Number of subjects: 0
Study 19914558 — intervention group
Group type: COMPARATOR
Intervention: Control group from randomized controlled trials
Number of subjects: 0
Study 17693976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen replacement therapy (2 mg/day)
Number of subjects: 41
Study 17693976 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (0.05 mg/day)
Number of subjects: 41
Study 17693976 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy female subjects, 47+/‐5 years)
Number of subjects: 41
Study 15767218 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate MR granules administered once/day or twice/day (500 mg)
Number of subjects: 75
Study 15767218 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate MR granules administered with yogurt or after a high-fat meal
Number of subjects: 75
Study 15767218 — intervention group
Group type: COMPARATOR
Intervention: Existing valproate SR formulations
Number of subjects: 75
Study 15767218 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate MR granules
Number of subjects: 75
Study 12410497 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) orally (600 mg) plus saline every 12 hr for 24 hr before and after the procedure
Number of subjects: 123
Study 12410497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg/kg/min) plus saline for 4 hr prior and 4 hr after the procedure
Number of subjects: 123
Study 12410497 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.45% normal saline at 1 cc/kg) for 12 hr before and 12 hr after the procedure
Number of subjects: 123
Study 10519498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine (2.5 microg/ml)
Number of subjects: 8
Study 10519498 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine (1%)
Number of subjects: 8
Study 8550123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine nitrate (2%) 10 microliters
Number of subjects: 12
Study 8550123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine nitrate (2%) 20 microliters
Number of subjects: 12
Study 8550123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine nitrate (2%) 40 microliters
Number of subjects: 12
Study 8550123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine nitrate (2%) 80 microliters
Number of subjects: 12
Study 1741534 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (T)
Number of subjects: 12
Study 1741534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 6127901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (20 mg in controlled release preparation)
Number of subjects: 0
Study 6127901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (oral administration)
Number of subjects: 0
Study 6127901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (intravenous administration)
Number of subjects: 0
Study 6127901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (intravenous dose)
Number of subjects: 0
Study 6127901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (oral dose)
Number of subjects: 0
Study 6127901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 0
Study 6127901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (solution)
Number of subjects: 0
Study 30565716 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural modification programme
Number of subjects: 68
Study 30565716 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 68
Study 29346837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (100 mg; supratherapeutic dose)
Number of subjects: 42
Study 29346837 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg; positive control)
Number of subjects: 42
Study 29346837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27503124 — intervention group
Group type: EXPERIMENTAL
Intervention: Weng-li-tong (WLT)
Number of subjects: 182
Study 27503124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 182
Study 27503124 — intervention group
Group type: EXPERIMENTAL
Intervention: Weng-li-tong plus Tolterodine
Number of subjects: 182
Study 27503124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 24616624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneroid Blood Pressure (ABP) monitoring
Number of subjects: 50
Study 24616624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometric Blood Pressure (OBP) monitoring
Number of subjects: 50
Study 22246026 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion (1.5 μg/min for 20 min)
Number of subjects: 18
Study 22246026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22246026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneous)
Number of subjects: 18
Study 19439741 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 600
Study 19439741 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide plus doxorubicin)
Number of subjects: 600
Study 18026240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuidex (4 x 1.4 mL) submucosally injected
Number of subjects: 4
Study 15532079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alpha (2.5 mg daily)
Number of subjects: 48
Study 15532079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study 11988603 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) examination
Number of subjects: 47
Study 11133852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporin A
Number of subjects: 158
Study 11133852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporin A
Number of subjects: 158
Study 11133852 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 158
Study 9772947 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (2 tablets)
Number of subjects: 10
Study 9772947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7840711 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin, Macropen, Azithromycin
Number of subjects: 0
Study 7840711 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 3046629 — intervention group
Group type: EXPERIMENTAL
Intervention: Capozide 25/15
Number of subjects: 24
Study 3046629 — intervention group
Group type: EXPERIMENTAL
Intervention: Capozide 50/15
Number of subjects: 24
Study 3046629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8205595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole and amoxicillin
Number of subjects: 0
Study 8205595 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole alone
Number of subjects: 0
Study 364059 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline administered before and during the first three postoperative days
Number of subjects: 0
Study 364059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31288751 — intervention group
Group type: EXPERIMENTAL
Intervention: Gift certificate (50 EUR)
Number of subjects: 698
Study 31288751 — intervention group
Group type: COMPARATOR
Intervention: Lottery (two prizes of 500 EUR and 1000 EUR)
Number of subjects: 698
Study 31288751 — intervention group
Group type: COMPARATOR
Intervention: Handwritten name and address
Number of subjects: 698
Study 31288751 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed label
Number of subjects: 698
Study 31288751 — intervention group
Group type: COMPARATOR
Intervention: Postal invitation
Number of subjects: 698
Study 31288751 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail invitation
Number of subjects: 698
Study 29389753 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA
Number of subjects: 282
Study 26757466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol coils treatment
Number of subjects: 100
Study 26757466 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 25022821 — intervention group
Group type: EXPERIMENTAL
Intervention: High-output (therapeutic) stimulation
Number of subjects: 41
Study 25022821 — intervention group
Group type: COMPARATOR
Intervention: Low-output (active control) stimulation
Number of subjects: 41
Study 22485233 — intervention group
Group type: EXPERIMENTAL
Intervention: Proseal Laryngeal Mask Airway (PLMA)
Number of subjects: 80
Study 22485233 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 80
Study 20642548 — intervention group
Group type: EXPERIMENTAL
Intervention: febuxostat 80 mg + hydrochlorothiazide 50 mg
Number of subjects: 36
Study 20642548 — intervention group
Group type: COMPARATOR
Intervention: febuxostat 80 mg alone
Number of subjects: 36
Study 17667643 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal cardiorespiratory fitness (measured during a maximal test on a cycle ergometer)
Number of subjects: 2845
Study 15832147 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft bandage
Number of subjects: 39
Study 15832147 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 39
Study 12058515 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy for cognitive-perceptual abilities
Number of subjects: 832
Study 12058515 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy for motor capacities
Number of subjects: 832
Study 12058515 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory splinting
Number of subjects: 832
Study 10548709 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlarged port site (group A)
Number of subjects: 31
Study 10548709 — intervention group
Group type: COMPARATOR
Intervention: Culdotomy opening (group B)
Number of subjects: 31